ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1716 • ACR Convergence 2020

    Predictors of Unacceptable Pain and Unacceptable Pain with Low Inflammation in Early Rheumatoid Arthritis

    Anna Eberhard1, Tor Olofsson2, Stefan Bergman3, Thomas Mandl4 and Carl Turesson5, 1Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden. Department of Rheumatology, Skåne University Hospital, Lund, Sweden., Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, 4Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, 5Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden

    Background/Purpose: Pain is a common and debilitating symptom in patients with rheumatoid arthritis (RA). In early RA it is usually due to ongoing inflammation and…
  • Abstract Number: 1732 • ACR Convergence 2020

    Machine Learning Coupled with Patient Reported Outcome Data to Classify & Predict RA Disease Activity

    Jeffrey R Curtis1, Fenglong Xie2, Shelly Kafka3 and Shawn Black3, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Janssen Scientific Affairs, LLC, Horsham, PA

    Background/Purpose: Patient reported outcome (PRO) data have assumed increasing importance in the care of rheumatoid arthritis (RA) patients. However, physician-derived disease activity measures such as…
  • Abstract Number: 1749 • ACR Convergence 2020

    Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis

    Daniel Aletaha1, Rene Westhovens2, Cecile Gaujoux-Viala3, Giovanni Adami4, Alan Matsumoto5, Paul Bird6, Osvaldo Daniel Messina7, Maya Buch8, Beatrix Bartok9, Zhaoyu Yin9, Ying Guo10, Thijs Hendrikx11 and Gerd Burmester12, 1Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, 2University Hospitals Leuven, Belgium, Leuven, Belgium, 3Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France, 4University of Verona, Verona, Italy, 5Arthritis and Rheumatism Assoc, Wheaton, MD, 6University New South Wales, Sydney, Australia, 7IRO Medical Ctr & Cosme Argerich Hospital, Buenos Aires, Argentina, 8Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, 9Gilead Sciences, Inc., Foster City, CA, 10Gilead Sciences, Inc., Foster City, 11Galapagos BV, Leiden, Netherlands, 12Charité University Hospital Berlin, Berlin, Germany

    Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) with poor prognostic factors (PPF) are at risk for RA progression if disease activity is not rapidly controlled.…
  • Abstract Number: 1773 • ACR Convergence 2020

    Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)

    Christine Anastasiou1, Laura Trupin1, Patricia Katz2, Zara Izadi3, Milena Gianfrancesco1, Gabriela Schmajuk4 and Jinoos Yazdany5, 1University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, Novato, CA, 3University of California San Francisco, San Francisco, CA, 4University of California, San Francisco, Atherton, CA, 5UCSF, San Francisco, CA

    Background/Purpose: Prior studies suggest women with SLE and RA may have higher age-adjusted risk of adverse pregnancy outcomes. We evaluated maternal and fetal complications and…
  • Abstract Number: 1981 • ACR Convergence 2020

    Patients with Inflammatory Arthritis Who Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by Smartphone Apps: A Cross-sectional Study of 101 Patients, the ImBAIA Study

    Thomas Davergne1, Rawdha Tekaya2, Camille Deprouw3, Anne Tournadre4, Stéphane Mitrovic5, Adeline Ruyssen-Witrand6, Christophe Hudry7, Sabrina Dadoun8, Jérôme Avouac9, Kate Betteridge10, Bruno Fautrel11 and Laure Gossec12, 1Sorbonne University, INSERM, IPLES, Paris, France, 2Hôpital Charles Nicolle, Rheumatology department, Tunis, Tunisia, Tunis, Tunisia, 31. AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Paris, 75012, France, Paris, France, 4CHU Gabriel Montpied, Clermont-Ferrand, 5Institut Mutualiste Montsouris, Rheumatology department, Paris, France, Paris, Ile-de-France, France, 6Hôpital Purpan, CHU Toulouse, Toulouse, France, 7CeSOA, MGEN, Paris, France, Paris, Ile-de-France, France, 8Medical centre, Paris, France, paris, Ile-de-France, France, 9Cochin hospital, Rheumatology department, Paris, France, Paris, Ile-de-France, France, 10Patient research partner, UK, london, England, United Kingdom, 11Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, 12Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France

    Background/Purpose: Adherence to both medications and physical activity is insufficient in patients with inflammatory arthritis (IA), such as spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic…
  • Abstract Number: 2009 • ACR Convergence 2020

    Treat-to Target for Early RA Patients in Usual Clinical Practice, a Randomized Study with a Favorable Effect of a Second Oral Pulse of Prednisolone. the Amsterdam COBRA Treat-to-target Study

    Linda Hartman1, Linda Rasch2, Samina Turk3, Marieke ter Wee1, Pit Kerstens4, Conny van der Laken5, Mike Nurmohamed6, Dirkjan van Schaardenburg7, Lilian van Tuyl8, Alexandre Voskuyl1, Maarten Boers7 and Willem Lems1, 1Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, 2Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, 3Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands, 4Westfriesgasthuis, Hoorn, Netherlands, 5Amsterdam Rheumatology and immunology Center, location Amsterdam UMC, VU medical center, Amsterdam, Netherlands, 6Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, 7Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, 8Nivel, Utrecht, Netherlands

    Background/Purpose: EULAR guidelines advise to start with methotrexate (MTX) for early rheumatoid arthritis (RA), either alone or combined with prednisolone. Since this strategy is not…
  • Abstract Number: 0033 • ACR Convergence 2020

    Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy

    Matthew Wright1, Mette Kiel Smed2, J Lee Nelson3, Jørn Olsen4, Merete Hetland5, Vibeke Zoffmann2 and Damini Jawaheer6, 1UCSF Children's Hospital Oakland Research Institute, Oakland, CA, 2The Juliane Marie Center, Copenhagen, Denmark, 3Fred Hutchinson Cancer Res Ctr and U of WA, Seattle, WA, 4Aarhus University Hospital, Aarhus, Denmark, 5The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, 6UCSF Benioff Children's Hospital Oakland Research Institute, Oakland, CA

    Background/Purpose: Pregnancy is known to have disease-modifying effects on rheumatoid arthritis (RA). A role for long non-coding (lnc) RNAs in the improvement or worsening of…
  • Abstract Number: 0105 • ACR Convergence 2020

    Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients

    Balázs Juhász1, Katalin Gulyás1, Ágnes Horváth1, Edit Végh1, Anita Pusztai2, Ágnes Szentpétery3, Zsófia Pethő1, Nóra Bodnár1, Attila Hamar1, Levente Bodoki1, Harjit Bhattoa1, Éva Szekanecz1, Katalin Hodosi1, Andrea Domján1, Szilvia Szamosi1, Csaba Horváth4, Sándor Szántó1, Gabriella Szűcs1, Hennie Raterman5, Oliver FitzGerald6 and Zoltán Szekanecz1, 1University of Debrecen, Debrecen, Hungary, 2University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, 3Uppsala University Hospital, Uppsala, Sweden, 4Semmelweis University, Budapest, Hungary, 5Northwest Clinics, Alkmaar, Netherlands, 6Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland

    Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have both been associated with generalized and localized bone loss. Inflammatory cytokines like tumor necrosis factor (TNF)…
  • Abstract Number: 0152 • ACR Convergence 2020

    Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals

    Swathi Reddy1, Aricca Van Citters2, Rashmi Arora1, Kyawt Shwin1, Lisa Johnson2, Jabeen Ahmad2, Guy Eakin3, Eugene Nelson2, Andreas Reimold1 and Salahuddin Kazi1, 1Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, 2The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, 3Arthritis Foundation, Atlanta, GA

    Background/Purpose: Understanding patient goals and concerns is essential for aligning treatment decisions with patient preferences and supporting effective patient-clinician partnerships. Yet, little is known about…
  • Abstract Number: 0187 • ACR Convergence 2020

    Regional and Widespread Patterns of Non-articular Pain Are Common at RA Diagnosis and Contribute to Poor Outcomes at 12 Months: A Prospective Study of Pain Patterns in Canadians with RA

    Vivian Bykerk1, Orit Schieir2, Marie-France Valois3, Louis Bessette4, Gilles Boire5, Glen Hazlewood6, Carol Hitchon7, Edward C Keystone8, Diane Tin9, Carter Thorne9, Janet Pope10, Susan Bartlett3 and Canadian Early Arthritis Cohort (CATCH) Investigators11, 1Hospital for Special Surgery, New York, NY, 2Canadian Early Arthritis Cohort Study, Montreal, Canada, 3McGill University, Montreal, Canada, 4Laval University, Quebec, Canada, 5Universite de Sherbrooke, Sherbrooke, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Mount Sinai Hospital, Toronto, ON, Canada, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 11Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

    Background/Purpose: Persistent pain can occur in early RA patients, despite improvement in synovitis and may be due to coexisting non-articular pain (NAP). Though NAP is…
  • Abstract Number: 0203 • ACR Convergence 2020

    Safety of Baricitinib in Patients with Rheumatoid Arthritis: Interim Report from All-Case Post‑Marketing Study in Clinical Use

    Tatsuya Atsumi1, Nami Okamoto2, Nobunori Takahashi3, Naoto Tamura4, Atsuo Nakajima5, Ayako Nakajima6, Takao Fujii7, Hiroaki Matsuno8, Yuko Takahashi9, Fumie Inui9, Naoto Tsujimoto9, Atsushi Nishikawa9, Taeko Ishii9, Tsutomu Takeuchi10, Masataka Kuwana11 and Michiaki Takagi12, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, 2Department of Rheumatology and Allergy of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan, 3Department of Orthopaedics/Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, 5Ueno Touseki Clinic, Kitasaku District, Nagano, Japan, 6Center for Rheumatic Diseases, Mie University Hospital, Tsu, Mie, Japan, 7Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Wakayama, Japan, 8Matsuno Clinic for Rheumatic Diseases, Toyama, Toyama, Japan, 9Eli Lilly, Kobe, Hyogo, Japan, 10Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, 11Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, 12Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Yamagata, Japan

    Background/Purpose: To evaluate the safety of baricitinib in rheumatoid arthritis (RA) patients in clinical use.Methods: An all-case post-marketing study of baricitinib, started in September 2017,…
  • Abstract Number: 0219 • ACR Convergence 2020

    Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies

    Raquel Dos-Santos1, Sytske Anne Bergstra2, J. M. Maassen2, Thomas Huizinga2 and CF Allaart2, 1Clinical University Hospital in Santiago de Compostela, Santiago de Compostela, Galicia, Spain, 2Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Glucocorticoids are widely used in the treatment of rheumatoid arthritis (RA) patients. It is internationally recommended to taper and stop glucocorticoids as rapidly as…
  • Abstract Number: 0236 • ACR Convergence 2020

    Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial

    Rene Westhovens1, DaeHyun Yoo2, Piotr Wiland3, Marek Zawadzki4, Delina Ivanova5, Alfredo Berrocal Kasay6, Elias Chalouhi7, Eva Balázs8, SangJoon Lee9, SungHyun Kim9, JeeHye Suh9, NooRi Han9 and HoJae Lee9, 1University Hospitals Leuven, Belgium, Leuven, Belgium, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 3Medical Univeristy, Wroclaw, Poland, 4Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, 5Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, 6ABK Reuma SRL, LIMA, Peru, 7Clinica Internacional Sede Lima, Lima, Peru, 8Dr. Bugyi István Hospital, Szentes, Hungary, 9Celltrion, Inc., Incheon, Republic of Korea

    Background/Purpose: The subcutaneous (SC) formulation of CT-P13 received marketing authorization for RA from the EMA by demonstrating non-inferiority compared to CT-P13 intravenous for efficacy in…
  • Abstract Number: 0480 • ACR Convergence 2020

    Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort

    Julia Dupont1, Gregory Guernec2, Yannick Degboé3, Frédéric Lioté4, Olivier Vittecoq5, Arnaud Constantin6 and Adeline Ruyssen Witrand7, 1University Hospital of Thoulouse, Toulouse, 2Inserm UMR 1027, TOULOUSE CEDEX 9, France, 3University Hospital of Toulouse, Toulouse, 4AP-HP, Paris, France, 5University Hospital of Rouen, Rouen, France, 6Rheumatology Department, Toulouse University Hospital, Toulouse, France, 7Rheumatology center, University Hospital of Toulouse, Inserm 1027, University Paul Sabatier, Toulouse, France, Toulouse, France

    Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to target remission or at least low disease activity (LDA). We previously showed that SDAI remission…
  • Abstract Number: 0567 • ACR Convergence 2020

    Rheumatologist’s Perception of the Efficacy, Safety and Willingness to Prescribe Infliximab and Use Alternate Drug Supply Programs to Lower Cost of Rheumatoid Arthritis Care

    Cesar Galan1, Alan Puric2, Guy Cozzi2, Michele Hamburger3, Elisea Avalos-Reyes4 and Kjel Johnson1, 1CVS Health, Lincoln, RI, 2CVS Health, Northbrook, IL, 3Frances Hamburger Institute, Hauppauge, NY, 4CVS Health, Irving, TX

    Background/Purpose: There is interest in employing biosimilar therapies for patients with rheumatoid arthritis (RA), which have been shown comparable to originator biologics in safety and…
  • « Previous Page
  • 1
  • …
  • 156
  • 157
  • 158
  • 159
  • 160
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology